New drug aims to reactivate Cancer-Fighting genes in solid tumors

NCT ID NCT07303387

Recruiting now Disease control Sponsor: Gustave Roussy, Cancer Campus, Grand Paris Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing valemetostat, a daily pill, in 900 adults with advanced solid tumors that have specific gene changes (like SMARCB1 or ARID1A). The drug works by blocking EZH1/2 enzymes to reactivate genes that normally protect against cancer. The main goal is to see if the tumor shrinks or stops growing. Participants take the drug for up to two years and are monitored closely for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Valemetostat (a drug that blocks EZH1/2 enzymes to reactivate cancer-protecting genes)
What this could lead to: If it works, this could offer a new targeted treatment option for people with certain hard-to-treat solid tumors that have specific gene changes.
What could go wrong: This is an early phase 2 trial, so it is not yet proven to work. Side effects from valemetostat are possible, and the drug may not shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLEAR CELL ENDOMETRIAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer endometrial clear cell adenocarcinoma neoplasm ovarian cancer ovarian clear cell cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLEAR CELL ENDOMETRIAL CARCINOMA OVARIAN CANCER SOLID TUMOR MALIGNANCIES

Contacts and locations

Locations

Centre Léon Berard
NOT_YET_RECRUITING

Lyon, 69373, France
Gustave Roussy
RECRUITING

Villejuif, Val de Marne, 94805, France
Institut Bergonié
NOT_YET_RECRUITING

Bordeaux, 33076, France
Institut Curie
NOT_YET_RECRUITING

Paris, 75005, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.